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domains, including a short cytoplasmic domain at the NH 2 terminus followed by a putative transmembrane domain; a sperm protein, enterokinase, and agrin domain; two tandem C1r/C1s, urchin embryonic growth factor, and bone morphogenetic protein-1 (CUB) domains; four tandem low-density lipoprotein (LDL) receptor class A domains; and a trypsinlike serine protease domain at its COOH terminus (12, 19, 30, 31) . In addition to its role in cancer, expression of matriptase is observed mainly in most epithelium-containing tissues (24) . The distribution of matriptase suggests its role in epithelial biology. Indeed, matriptase is an essential component of the profilaggrin-processing pathway in keratinocytes and a key regulator of epidermal terminal differentiation (21) . These activities are important for epidermal barrier formation and postnatal survival as shown in matriptase-knockout mice (20) .
Besides its increased expression, such as in human breast cancer (10) , matriptase could play a role in cancer malignancy, such as in ovarian cancer, because of an imbalance of the protease relative to its cognate inhibitor, hepatocyte growth factor activator inhibitor 1 (HAI-1), in favor of proteolysis (23) . Furthermore, deregulated activation and aberrant subcellular localization of the protease may also contribute to its role in breast cancer malignancy (2) . In immortal mammary epithelial cells, activation of matriptase occurs at cell-cell junctions upon cellular stimulation with serum or sphingosine 1-phosphate (S1P) (1, 3, 7) . However, breast cancer cells constitutively activate matriptase and concentrate the activated protease at membrane ruffles (2) , a relocalization that may convert matriptase from a well-regulated cell junctional protease in mammary epithelial cells to a deregulated invasion protease at the leading edges of breast cancer cells. Furthermore, oligosaccharide modifications of matriptase by N-acetylglucosaminyltransferase V (GnT-V) in cancer cells could enhance the stability of matriptase, contributing to the prometastatic effect of GnT-V (8, 9) .
Activation of matriptase requires cleavage at its canonical activation motif to convert the single-chain zymogen to a two-chain active protease, a common theme for most of the serine proteases (1) . Interestingly, the activational cleavage of matriptase may not be carried out by other active proteases, because matriptase activation depends on its own active site triad and requires its noncatalytic domains and even its cognate inhibitor HAI-1 (25) . Therefore, we have proposed that the cleavage at the activation motif of one matriptase zymogen molecule may be preceded by the weak proteolytic activity of another matriptase zymogen molecule as a process of transactivation (25) . Dimerization or oligomerization of matriptase molecules thus may serve as a key step during matriptase autoproteolytic activation, a mechanism observed with C1r protease (5) and caspase 8 (33) . The noncatalytic domains and posttranslational modifications of matriptase, as well as LDL receptor class A domain of HAI-1, could provide the structural basis for the oligomerization of these molecules during matriptase activation (25) . In the present study, we sought to further understand the mechanisms that govern the process and regulation of matriptase autoproteolytic activation and the role of HAI-1 in matriptase functionality by characterizing and comparing the effects of two different exogenous inducers of matriptase activation in terms of the cellular events and signaling pathways involved in the activation of matriptase. Our data reveal that upon the stimulation of these two inducers, both matriptase and HAI-1 were translocated and accumulated at cell-cell junctions or vesicle-like structures where matriptase was activated. The close spatial association between matriptase and HAI-1 also allowed HAI-1 to inhibit active matriptase immediately after its activation.
MATERIALS AND METHODS

Chemicals and reagents.
Formaldehyde solution was purchased from EM Science/EM Industries (Bibbstown, NJ). Cytochalasin D, suramin, and Ro 31-8220 were obtained from Biomol (Plymouth Meeting, PA). All other chemical reagents were obtained from Sigma (St. Louis, MO) unless otherwise specified.
Cell lines and culture conditions. Immortalized 184 A1N4 human mammary epithelial cells, a gift from Dr. Martha Stampfer (Lawrence Berkeley National Laboratory, Berkeley, CA), were maintained routinely as previously described (1) . For time-kinetic and dose-response experiments, 184 A1N4 cells were seeded at a density of 1 ϫ 10 5 cells per well in a six-well plate for 2 days. Cells were treated with different concentrations of suramin or for various durations with 50 M suramin as indicated in the figure legends. Control cells were treated with DMSO alone. For immunofluorescent staining, 184 A1N4 cells were seeded in a well with a coverglass on the bottom of 12-well plates in improved minimum essential medium (IMEM) containing 0.5% FBS. Two days after being plated, cells were treated with 50 M suramin or 50 ng/ml S1P in IMEM for 30 min. Control cells were treated with DMSO alone. After the treatment, cells were stained with fluorescent dye-labeled monoclonal antibodies (MAb) as described in the figure legends.
Monoclonal antibodies. Human matriptase protein was detected using MAb M32, which interacts with the third LDL receptor class A domain of matriptase (7, 18) . The activated form of matriptase was detected using MAb M69, which recognizes an epitope present only in the activated (two-chain) form of the enzyme (1). Human HAI-1 was analyzed using MAb M19 (18) .
Conjugation of MAb with fluorescent dyes. To conjugate MAb with fluorescent dyes, 1 mg of MAb, including M32, M69, and M19, were dissolved in 0.1 M NaHCO 3 and then labeled with Alexa Fluor 488, 594, or 647 (Molecular Probes, Eugene, OR) according to the manufacturer's instructions.
Western blot analysis. Cell lysates for Western blotting were prepared by lysing cells in 1% Triton X-100 in PBS after the cells were washed twice in PBS. The nuclei and cell debris were removed by centrifugation at 10,000 g for 10 min at 4°C. The protein concentration was determined using bicinchoninic acid protein assay reagents (Pierce, Rockford, IL) according to the manufacturer's protocol. For immunoblotting, an aliquot of the total lysate protein was electrophoresed in a 7.5% SDS gel under nonboiled and nonreduced conditions and transferred onto Protran nitrocellulose membranes (Schleicher & Schuell, Keene, NH). The membranes were incubated with MAb as indicated, and the proteins were visualized using Western Lightning Chemiluminescence Reagent Plus (PerkinElmer, Boston, MA).
Immunodepletion. An aliquot of 400 l of total cell lysates from suramin-stimulated 184 A1N4 cells was incubated with 30 l of MAb M19-conjugated Sepharose 4B (5 mg of M19 per ml of Sepharose 4B beads) at 4°C for 2 h. The supernatant was separated from M19-Sepharose 4B by centrifugation.
Immunofluorescence microscopy. Cells were plated onto microcoverglasses and grown for 2 days. Subconfluent cells were subjected to the treatments indicated in each figure legend. Cells were then fixed in 3.7% formaldehyde and permeabilized within 0.05% Triton X-100 in PBS for 20 min at room temperature. Cells were washed with PBS three times. Matriptase, activated matriptase, and HAI-1 were detected with Alexa Fluor dye-conjugated M32, M69, and M19, respectively. F-actin was visualized using Texas red-labeled phalloidin (Molecular Probes), and nuclei were stained with 4Ј,6-diamidino-2-phenylindole (DAPI). FITC-labeled anti-mouse IgG was used for the staining controls, which resulted in a weak, diffuse background (data not shown). After fluorescent staining, coverglasses were mounted with Prolong Antifade (Molecular Probes) and the fluorescent images were captured using the MetaVue software package (Universal Imaging, Downingtown, PA) in conjunction with a Nikon Eclipse E600 digital fluorescence microscope.
RESULTS
In previous studies (1, 3, 7) , investigators at our laboratory showed that S1P, a lysophospholipid with pleiotropic, growth factor-like activity, induced matriptase translocation to and activation at cell-cell contacts of 184 A1N4 immortal human mammary epithelial cells. S1P also simultaneously induces actin cytoskeletal rearrangement, cell shape changes, formation of subcortical actin belts, and assembly of adherens junctions in 184 A1N4 cells. These S1P-induced cellular events are thought to be induced mainly via S1P receptors, members of the endothelial differentiation gene family (16, 32) . While we were investigating the role of S1P receptors in the activation of matriptase, we noticed that suramin, a sulfide-rich, anionic small molecule, could induce activation of matriptase to much higher levels than S1P could, but that did not change cell morphology. In the present study, we investigated how suramin induced matriptase activation in mammary epithelial cells by comparing it with S1P and set out to discern any common mechanisms for matriptase activation using each inducer.
Suramin-induced matriptase activation in immortal human mammary epithelial cells.
To analyze the effect of suramin on the activation of matriptase, we first determined the optimal concentration ( Fig. 1A ) and time course (Fig. 1B ) of cellular treatments using this compound. Matriptase activation was determined by the levels of activated matriptase using immunoblot analysis of cell lysates and immunofluorescent staining of fixed cells. For these studies, we used MAb M69, which specifically recognizes the two-chain activated matriptase but not the single-chain zymogen (1) . Activation of matriptase induced by suramin occurred in a dose-responsive manner, with a minimal required concentration of 25 M (Fig. 1A) . The activated matriptase was detected in complexes with its cognate inhibitor, HAI-1, at 120 and 85 kDa (Figs. 1 and 2). We also used another anti-matriptase MAb, M32, to determine the levels of matriptase. M32 MAb recognizes the third LDL receptor class A domain of matriptase (7) and thus can react with the single-chain latent protease of 70 kDa and with two-chain activated matriptase in the 120-kDa HAI-1 complex, but not with the 85-kDa HAI-1 complex, which likely contains the serine protease domain of matriptase and the full-length HAI-1 (Fig. 2 ). M32 reactivity provided data indicating the extent to which latent matriptase is converted to its activated form by comparing the levels of the 70-kDa form in controls with those in treated samples. For example, the majority of matriptase was converted to its activated form with 50 and 100 M suramin. Matriptase-HAI-1 complexes induced by suramin also were observed to appear in a dose-responsive manner in association with anti-HAI-1 MAb M19. M19 recognizes the unbound, full-length HAI-1 at 55 kDa and both the 120-and 85-kDa matriptase-HAI-1 complexes (Fig. 1A) . In contrast to matriptase, however, the majority of HAI-1 was detected in its unbound form, even after treatment with 100 M suramin. These data suggest that the complexed HAI-1 represents only a small portion of total HAI-1, even under conditions in which the majority of matriptase is activated and bound to HAI-1. Therefore, 184 A1N4 cells express HAI-1 in much higher ratios than matriptase. Matriptase activation was detected within 5 min of suramin treatment and reached to the maximal activation after 30-min treatment (Fig. 1B) . This rapid response of matriptase activation is similar to that observed with S1P (3).
Inhibition of matriptase by HAI-1 simultaneously follows the activation of protease.
To further confirm that the 120-and 85-kDa bands detected using these three MAb were matriptase-HAI-1 complexes, we first immunodepleted cell lysates of suramin-treated 184 A1N4 cells using anti-HAI-1 MAb M19. Subsequently, we examined the depletion of both 120-and 85-kDa bands on immunoblots using anti-HAI-1 MAb M19, Fig. 2 . Detection of all activated matriptase in HAI-1 complexes. A: confirmation that 120-and 85-kDa bands are matriptase-HAI-1 complexes. To confirm that the 120-and 85-kDa bands are matriptase-HAI-1 complexes, the cell lysates of suramin-treated 184 A1N4 cells were immunodepleted (IP) using anti-HAI-1 MAb M19-Sepharose 4B. The total cell lysate (L) and the MAb M19-depleted cell lysate (D) were analyzed using Western blotting with anti-HAI-1 MAb M19, anti-two-chain matriptase MAb M69, and antimatriptase MAb M32. B: the 85-kDa matriptase-HAI-1 complex is derived from the 120-kDa complex. Suramin-stimulated cells were lysed in lysis buffers with or without 5,5Ј-dithiobis-(2-nitrobenzoic acid) (DTNB). These cell lysates were incubated at 4°C or 37°C for 5 min as indicated. The samples were examined using immunoblot analysis with MAb M19, M32, and M69, respectively. C: a proposed model for the conversion of the matriptase-HAI-1 complex from the 120-to 85-kDa forms. The serine protease domain (SPD) of activated matriptase binds to the first Kunitz domain (KD1) of HAI-1 to form the 120-kDa complex. A proposed cleavage at the disulfide bond, which connects SPD with noncatalytic domain of matriptase, occurs via the action of protein disulfide isomerase (PDI) to generate the 85-kDa complex, which contains only the SPD of matriptase and full-length HAI-1. The epitope recognized by MAb M32 on the third LDL receptor class A domain is lost in the 85-kDa complex, along with the loss of noncatalytic domain of matriptase. Both epitopes, recognized by MAb M69 and M19, are preserved in the 85-kDa complex. anti-matriptase MAb M32, and anti-two-chain matriptase MAb M69 ( Fig. 2A) . These combinations of immunodepletion and immunoblot confirmed that the protein bands of the same size recognized by different MAb on immunoblots were the same proteins. As expected, anti-HAI-1 MAb M19 almost completely depleted the 120-, 85-, and 55-kDa bands recognized by M19 using immunoblotting. Both 120-and 85-kDa bands recognized by MAb M69 using immunoblotting, but not the 70-kDa band recognized by MAb M32, were also depleted by anti-HAI-1 MAb M19. The depletion of the 120-, 85-, and 55-kDa bands, and the lack of immunodepletion of the 70-kDa matriptase bands, by anti-HAI-1 MAb M19 provide evidence that the immunodepletion was specific. These data also confirm that both 120-and 85-kDa bands were matriptase-HAI-1 complexes. The 85-kDa matriptase-HAI-1 complex was previously suggested to be the free form of activated matriptase (1, 3, 25) . However, the present data suggest that all activated matriptase is bound with HAI-1 immediately after its generation.
It is possible that the 85-kDa complex is derived from the 120-kDa complex. Indeed, the 120-kDa complex was converted to the 85-kDa complex by incubating the cell lysate at 37°C (Fig. 2B) . Because MAb M32 did not recognize the 85-kDa complex, the conversion of the 120-kDa complex to a 85-kDa complex could result from the loss of the noncatalytic domains of matriptase, which contain its third LDL receptor class A domain, where the epitope recognized by M32 resides. Furthermore, the addition of 5,5Ј-dithiobis-(2-nitrobenzoic acid) (DTNB) into the cell lysis buffer inhibited this conversion even for the samples incubated at 37°C. Because the loss of noncatalytic domains of matriptase occurred only for activated matriptase and not for latent matriptase, and because DTNB can inhibit protein disulfide isomerase (15) , it is very likely that, after cell lysis, protein disulfide isomerase cleaves the disulfide bond that connects the noncatalytic domains with the serine protease domain of activated matriptase. For singlechain matriptase, if cleavage of this disulfide linkage by protein disulfide isomerase occurs, the serine protease domain will not separate from the noncatalytic domain, because the protease will still be held as single-chain matriptase by peptide bonds. Figure 2C summarizes our current theory that the 85-kDa matriptase complex is derived from the 120-kDa complex and shows the positions of epitopes recognized by the three MAb that we used. S1P and suramin induce accumulation and activation of matriptase at activation foci. While both S1P and suramin induce matriptase activation in 184 A1N4 cells and share several common characteristics, such as dose-response relationship, rapid kinetics, and rapid inhibition of active matriptase by HAI-1, we have observed some differences between them. Specifically, suramin requires micromolar concentration, compared with nanomolar concentration for S1P, to induce matriptase activation. Also, compared with S1P-treated cells, much higher proportions of latent matriptase were converted to activated matriptase in suramin-treated cells. In addition, S1P simultaneously induced changes in cell shape under the light microscope, but such changes were not observed with suramin. The S1P-induced changes in cell shape were associated mainly with the S1P-induced actin cytoskeletal rearrangement, that is, the formation of actin subcortical belts. Furthermore, destruction of actin cytoskeletal rearrangement inhibits S1P-induced matriptase activation (7). Therefore, it is of interest to investigate the role of the cellular events, particularly actin cytoskeletal rearrangement, in suramin-induced matriptase activation. In Fig. 3 , we compared suramin with S1P for their abilities to induce the redistribution of matriptase and cause actin cytoskeletal rearrangement. After growing cells in IMEM supplemented with 0.5% FBS for 2 days, matriptase was observed mainly in the cytoplasm with diffuse staining patterns (Fig. 3A) . Little F-actin was observed in these cells (Fig. 3B) . After 30 min of suramin treatment, while matriptase was still located in cytoplasm, the protease apparently concentrated at vesicle-like structures with various sizes (Fig. 3D) , in striking contrast to the cell-cell contact localization of matriptase induced by S1P (Fig. 3G) . While filamentous actin structures were increased by S1P treatment (Fig. 3H ), they were much less organized in suramin-treated cells (Fig.  3E) . Interestingly, pretreatment with suramin apparently did not affect the S1P-induced formation of subcortical actin belts and translocation of matriptase to cell-cell contacts (Fig. 3, J 
and K).
We further examined the appearance and localization of activated matriptase (red) using Alexa Fluor 647-labeled MAb M69 in conjunction with total matriptase (green) using Alexa Fluor 488-labeled MAb M32 (Fig. 4) . Despite high levels of total matriptase in the cytoplasm, activated matriptase was not detected using immunofluorescent staining in 184 A1N4 cells after growth for 2 days (1, 3, 7) . Thirty minutes after suramin treatment, activated matriptase was detected as spotty vesiclelike structures in cytoplasm (Fig. 4B) , a pattern similar to total matriptase (Figs. 4A and 3D ). When both images were merged, activated matriptase coincided with the spotty total matriptase (Fig. 4C) . The localization of activated matriptase, as well as the total matriptase, in suramin-treated 184 A1N4 cells was different from that in S1P-treated cells, where activated matriptase was colocalized with total matriptase at cell-cell contacts (Fig. 4, D-F) . Despite these differences, activated matriptase appeared where total matriptase accumulated. In S1P-treated cells, activated matriptase was exclusively detected at cell-cell contacts, particularly where more total matriptase accumulated. Similarly to S1P-treated cells, suramin treatment caused accumulation of matriptase, but now in the cytoplasm, as spotty, vesicle-like structures, where its activation may occur. Again, cellular pretreatment with suramin did not affect subsequent S1P-induced translocation of both latent matriptase and activated matriptase to cell-cell junctions (Fig. 4, G-I ). These data suggest that accumulation of matriptase is a common theme for its activation, either at cell-cell contacts in S1P-treated cells or in cytoplasm as spotty, vesicle-like structures in suramin-treated cells. These observations are consistent with our hypothesis that matriptase activation occurs via autoproteolytic activation, in that dimerization or oligomerization of latent matriptase molecules occurs, leading to their cross-activational cleavage (25) . Accumulation of matriptase at cell-cell junctions or in the cytoplasm as spotty, vesicle-like structures, which we term "activation foci," provides the platform for latent matriptase molecules to interact with each other.
HAI-1 is translocated to activation foci for matriptase activation in response to S1P or suramin treatment. HAI-1 was initially identified to be the cognate inhibitor of matriptase (18, 26) , and subsequently its role in matriptase activation was demonstrated (25). The extremely rapid, highly efficient inhi-bition of matriptase by HAI-1, coupled with the requirement of HAI-1 for matriptase activation, suggest that the inhibitor should be in physical proximity to matriptase during activation of the protease. After growth of 184 A1N4 cells for 2 days, the inhibitor and matriptase were localized in the cytoplasm, surrounding the nuclei (Fig. 5, A-C) . Both proteins were cotranslocated to cell-cell contacts in response to S1P treatment (Fig.  5, D-F) and appeared in the spotty, vesicle-like structures in the cytoplasm in response to suramin treatment (Fig. 5, G-I) . These results suggest that HAI-1 and matriptase are translocated to activation foci for the activation of matriptase. Therefore, for matriptase autoproteolytic activation, both S1P and suramin may translocate matriptase, HAI-1, and other unidentified components to the activation foci to form the activation complex.
F-actin polymerization is not required for suramin-induced matriptase activation. Previously, we showed that S1P-induced matriptase translocation and activation at cell-cell contacts was dependent on actin cytoskeletal rearrangement (7). Therefore, it was of interest to investigate the role of actin cytoskeletal rearrangement in suramin-induced matriptase activation. As expected, activation of matriptase by S1P was significantly suppressed by pretreatment of 0.1 M cytochalasin D, which causes disruption of actin filaments and inhibition of actin polymerization (Fig. 6B) . However, cytochalasin D up to 1 M concentration failed to block matriptase activation induced by suramin (Fig. 6A) . These data are parallel to the fact that suramin does not induce formation of subcortical actin belts and suggest that actin filament polymerization is not required for suramin-induced accumulation and activation of matriptase.
Both S1P-and suramin-induced matriptase activation was inhibited by Ro 31-8220. Because S1P induces various signal pathways, which may participate in matriptase activation, we ( Fig. 7B) , suggesting the role of PKC in matriptase activation. Other chemicals showed no obvious effect on the S1P-induced activation of matriptase (data not shown). Interestingly, despite differential response to cytochalasin D, both S1P-induced and suramin-induced matriptase activation was inhibited by Ro 31-8220 (Fig. 7) . These data suggest that both S1P and suramin may share some common regulatory mechanisms for their ability to induce matriptase activation.
DISCUSSION
From a biochemical point of view, the process of matriptase activation represents a proteolytic cleavage at its canonical serine protease activation motif, converting the single-chain zymogen to the two-chain, active protease. If this process is carried out by other active proteases, as is the case for most serine proteases, one could expect that matriptase activation will be a simple matter by the regulation of its protease activator. However, our data indicate that matriptase activation is a complex process, because the current results show that the translocation of matriptase to activation foci, the formation of putative activation complex, and the involvement of protein kinases are required for it to occur and because previous studies conducted at our laboratory showed that matriptase activation requires its own intact active triads and noncatalytic domains, and even its cognate inhibitor HAI-1. Thus all of these data suggest that matriptase activation occurs through a tightly regulated process; importantly, its activation is dependent on its own protease activity but is not based on other active proteases. In immortal mammary epithelial cells, this activation event can be induced either by its physiological inducer S1P to occur at cell-cell junctions or by chemical inducer suramin to occur at vesicle-like structures. In activation foci, the cleavage of matriptase at the canonical activation motif of its zymogen may be carried out by another matriptase zymogen molecule as a process of transactivation. Activation by zymogens could serve as the major mechanism for subse- quent matriptase activation along the cell-cell contacts (in the case of S1P stimulation) or at the vesicle-like structures (in the case of suramin stimulation). Because the cleavage preference of matriptase perfectly matches the flanking sequences of its activation motif, the newly produced, active matriptase may also activate latent matriptase. However, this possibility could depend on the competition for active matriptase among the latent matriptase, its physiological substrates (as yet unknown), and its competitive inhibitor HAI-1.
HAI-1 was initially identified as a cognate matriptase inhibitor (18) and was subsequently shown also to be required for matriptase activation (25) . Its inhibitory role results from the binding of its first Kunitz domain with active matriptase (14) . However, its participation in matriptase activation is mainly via its LDL receptor class A domain, which could provide the structural basis for protein-protein interactions in the formation of matriptase activation complexes. The translocation and concentration of both matriptase and HAI-1 in activation foci in response to cellular stimulation by suramin or S1P further support the close temporospatial relationship between these two molecules during matriptase activation. Therefore, HAI-1 may directly or indirectly contact latent matriptase in the activation complex. This close spatial proximity of HAI-1 to active matriptase must result in a very efficient and rapid inhibition of active matriptase immediately after matriptase activation. This inhibitor-dependent activation could be the explanation for all activated matriptase in HAI-1 complexes (Figs. 1 and 2 ). The coupling of matriptase activation with its inhibition apparently makes the half-life of active matriptase very short. Therefore, it is plausible that the substrates of matriptase may also be present in the activation foci or that the matriptase substrates could even be required for full matriptase activation. This mechanism could allow matriptase activation, action on substrates, and inhibition to occur simultaneously.
The dual role of HAI-1 in matriptase activation and inhibition appears to be reminiscent of the role of tissue inhibitor of matrix metalloproteinase-2 (TIMP-2) in the regulation of matrix metalloproteinase-2 (MMP-2). It has been established that MMP-2 activation occurs via a mechanism to form a trimolecular complex of TIMP-2, MMP-2 zymogen, and MT1-MMP in 1:1:1 stoichiometry (11) . When the concentration of TIMP-2 is low, TIMP-2 cannot bind to active MMP-2, leading to collagen degradation by these active MMP-2. At the high concentration of TIMP-2, TIMP-2 functions as a great inhibitor to block MMP-2 activity (13) . Similarly, HAI-1 is necessary to form oligomeric complexes with matriptase zymogens and/or other yet identified proteins to facilitate matriptase activation. The coupling of protease activation with inhibition ensures a tight control in the protease function, avoiding harmful effects of proteolysis.
Because matriptase is likely to be activated via autoproteolytic activation and because only the first protease in a protease cascade needs this activation mechanism, we have hypothesized that matriptase may be at the pinnacle of an as yet poorly characterized protease cascade. The complicated regulatory mechanisms that govern matriptase activation, action on its substrates, inhibition, and subcellular localization seem parallel to its potential leading position in a protease cascade. By these regulatory mechanisms, activation of matriptase and the putative protease cascade would occur only at the right time, when the exogenous inducers were present, and only at the right place, such as at cell-cell junctions where its substrates might be colocalized or cotranslocated. Depletion of the exogenous inducers, as well as HAI-1 inhibition, provides the mechanisms for fast and timely switch-off of the protease cascade. Ectodomain shedding of matriptase-HAI-1 complexes could be the mechanism for their cellular clearance.
Although S1P and suramin induce matriptase activation at different subcellular locations, both activation inducers cause translocation and accumulation of matriptase, HAI-1, and probably other required components at activation foci. These common processes for matriptase activation indicate some basic mechanisms for matriptase activation: the involvement of the cell membrane and intracellular signaling. Both cell-cell junctions and vesicle-like structures contain lipid biolayers for the anchoring and trafficking of these proteins, consistent with the transmembrane protein characteristics of matriptase and HAI-1. The involvement of PKC-like protein kinases in both S1P-and suramin-induced matriptase activation suggests that intracellular signaling may contribute to the trafficking and oligomerization of these proteins at activation foci, consistent with the role of PKC in vesicle trafficking (4) . Interestingly, this protein kinase-based intracellular signaling appears to depend on the assembly of F-actin and adherens junctions in response to S1P stimulation; suramin, however, could induce this intracellular signaling in the absence of F-actin.
In conclusion, in response to exogenous activation inducers, matriptase, its cognate inhibitor HAI-1, and possibly other unidentified proteins translocate and accumulate at activation foci, either at cell-cell junctions or at vesicle-like structures inside cells. Activation foci provide a good milieu in which matriptase can interact with those essential components and initiate matriptase activation. After its activation, active matriptase is rapidly bound to HAI-1. Subsequently, the matriptase-HAI-1 complex is shed into the extracellular milieu. Thus our data indicate that activation and HAI-1-mediated inhibition of matriptase are well organized and controlled at activation foci in human mammary epithelial cells. 
